Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib versus mycophenolate mofetil for lichen planopilaris
IRCT20190325043107N86Phase 3Recruiting
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in lichen planopilaris (LPP) comparing Tofacitinib with Mycophenolate mofetil (2 arms). Primary endpoint: Disease severity. Started Oct 2026; status: recruiting.
02
Drugs
tofacitinibmycophenolate mofetil
03
Conditions
lichen planopilaris (LPP)
Beyond the preview
Go deeper on IRCT20190325043107N86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190325043107N86.